FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296841146> ?p ?o ?g. }

• W4296841146 abstract "Primary percutaneous coronary intervention (PPCI) is the most effective treatment strategy for ST-segment elevation myocardial infarction (STEMI). Nevertheless, dysregulated inflammation induced by myocardial reperfusion injury may increase the final infarct size and induce maladaptive myocardial remodeling. Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor, as a novel and potent lipid-lowering drug, plays an important role in inflammation. The aim of this study is to investigate whether the early application of PCSK9 inhibitor can increase the myocardial salvage index (MSI) and improve ventricular remodeling in patients with STEMI.The PERFECT II trial is a prospective, open-label, multicenter, randomized controlled study involving 160 patients with STEMI who are scheduled to undergo PPCI. The eligible patients will be divided into PCSK9 inhibitor group and control group via the interactive web response system, at a 1:1 ratio. In the PCSK9 inhibitor group, the PCSK9 inhibitor alirocumab at a dose of 75 mg will be subcutaneously injected immediately after PPCI and administered every 2 weeks thereafter for 3 months based on conventional treatment. In the control group, conventional treatment will be administered. The primary endpoint is MSI, as measured by cardiac magnetic resonance imaging (CMR) at 1 week after PPCI. The secondary endpoints are the peak time of creatine kinase (CK)-MB and troponin I (TnI)/TnT after PPCI; the postoperative fall time of the ST segment on electrocardiography (ECG); the rate of plasma low-density lipoprotein cholesterol (LDL-C) compliance (< 1.4 mmol/L and a reduction of >50% from baseline) at 1, 3, and 6 months after PPCI; infarct size and ejection fraction (EF) measured by CMR at 6 months after PPCI; the occurrence of major adverse cardiovascular event (MACE: a composite of cardiovascular death, non-fatal myocardial infarction, stent thrombosis, repeat revascularization, stroke, and heart failure needed to be hospitalized).This is the first multicenter study to investigate the effect of early application of the PCSK9 inhibitor alirocumab on MSI in patients with STEMI undergoing PPCI. The findings will provide an opportunity to explore novel ideas and methods for the treatment of acute myocardial infarction.ClinicalTrials.gov, identifier: NCT05292404." @default.
• W4296841146 created "2022-09-24" @default.
• W4296841146 creator A5011982751 @default.
• W4296841146 creator A5044544424 @default.
• W4296841146 creator A5046454314 @default.
• W4296841146 creator A5056496295 @default.
• W4296841146 creator A5062459110 @default.
• W4296841146 creator A5067937579 @default.
• W4296841146 creator A5081028446 @default.
• W4296841146 creator A5084887958 @default.
• W4296841146 creator A5086526025 @default.
• W4296841146 creator A5088914905 @default.
• W4296841146 creator A5089103033 @default.
• W4296841146 creator A5090117430 @default.
• W4296841146 date "2022-09-23" @default.
• W4296841146 modified "2023-09-30" @default.
• W4296841146 title "Impact of early PCSK9 inhibitor treatment on heart after percutaneous coronary intervention in patients with STEMI: Design and rationale of the PERFECT II trial" @default.
• W4296841146 cites W1042476336 @default.
• W4296841146 cites W1996626325 @default.
• W4296841146 cites W2001328643 @default.
• W4296841146 cites W2043355876 @default.
• W4296841146 cites W2107313543 @default.
• W4296841146 cites W2147284855 @default.
• W4296841146 cites W2299478536 @default.
• W4296841146 cites W2334744705 @default.
• W4296841146 cites W2337488815 @default.
• W4296841146 cites W2468204122 @default.
• W4296841146 cites W2596179513 @default.
• W4296841146 cites W2609836833 @default.
• W4296841146 cites W2654759377 @default.
• W4296841146 cites W2752033985 @default.
• W4296841146 cites W2753051611 @default.
• W4296841146 cites W2754054868 @default.
• W4296841146 cites W2795780364 @default.
• W4296841146 cites W2801426688 @default.
• W4296841146 cites W2804936789 @default.
• W4296841146 cites W2940899024 @default.
• W4296841146 cites W2946105917 @default.
• W4296841146 cites W2990333463 @default.
• W4296841146 cites W3197233987 @default.
• W4296841146 cites W4211143906 @default.
• W4296841146 doi "https://doi.org/10.3389/fcvm.2022.1009674" @default.
• W4296841146 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36211588" @default.
• W4296841146 hasPublicationYear "2022" @default.
• W4296841146 type Work @default.
• W4296841146 citedByCount "1" @default.
• W4296841146 countsByYear W42968411462023 @default.
• W4296841146 crossrefType "journal-article" @default.
• W4296841146 hasAuthorship W4296841146A5011982751 @default.
• W4296841146 hasAuthorship W4296841146A5044544424 @default.
• W4296841146 hasAuthorship W4296841146A5046454314 @default.
• W4296841146 hasAuthorship W4296841146A5056496295 @default.
• W4296841146 hasAuthorship W4296841146A5062459110 @default.
• W4296841146 hasAuthorship W4296841146A5067937579 @default.
• W4296841146 hasAuthorship W4296841146A5081028446 @default.
• W4296841146 hasAuthorship W4296841146A5084887958 @default.
• W4296841146 hasAuthorship W4296841146A5086526025 @default.
• W4296841146 hasAuthorship W4296841146A5088914905 @default.
• W4296841146 hasAuthorship W4296841146A5089103033 @default.
• W4296841146 hasAuthorship W4296841146A5090117430 @default.
• W4296841146 hasBestOaLocation W42968411461 @default.
• W4296841146 hasConcept C126322002 @default.
• W4296841146 hasConcept C164705383 @default.
• W4296841146 hasConcept C168563851 @default.
• W4296841146 hasConcept C203092338 @default.
• W4296841146 hasConcept C2777995511 @default.
• W4296841146 hasConcept C2778163477 @default.
• W4296841146 hasConcept C2780072125 @default.
• W4296841146 hasConcept C2780400711 @default.
• W4296841146 hasConcept C2780745583 @default.
• W4296841146 hasConcept C2780902209 @default.
• W4296841146 hasConcept C2780948078 @default.
• W4296841146 hasConcept C43554185 @default.
• W4296841146 hasConcept C500558357 @default.
• W4296841146 hasConcept C71924100 @default.
• W4296841146 hasConceptScore W4296841146C126322002 @default.
• W4296841146 hasConceptScore W4296841146C164705383 @default.
• W4296841146 hasConceptScore W4296841146C168563851 @default.
• W4296841146 hasConceptScore W4296841146C203092338 @default.
• W4296841146 hasConceptScore W4296841146C2777995511 @default.
• W4296841146 hasConceptScore W4296841146C2778163477 @default.
• W4296841146 hasConceptScore W4296841146C2780072125 @default.
• W4296841146 hasConceptScore W4296841146C2780400711 @default.
• W4296841146 hasConceptScore W4296841146C2780745583 @default.
• W4296841146 hasConceptScore W4296841146C2780902209 @default.
• W4296841146 hasConceptScore W4296841146C2780948078 @default.
• W4296841146 hasConceptScore W4296841146C43554185 @default.
• W4296841146 hasConceptScore W4296841146C500558357 @default.
• W4296841146 hasConceptScore W4296841146C71924100 @default.
• W4296841146 hasLocation W42968411461 @default.
• W4296841146 hasLocation W42968411462 @default.
• W4296841146 hasLocation W42968411463 @default.
• W4296841146 hasOpenAccess W4296841146 @default.
• W4296841146 hasPrimaryLocation W42968411461 @default.
• W4296841146 hasRelatedWork W1986689269 @default.
• W4296841146 hasRelatedWork W2011576613 @default.
• W4296841146 hasRelatedWork W2038640015 @default.
• W4296841146 hasRelatedWork W2127687375 @default.
• W4296841146 hasRelatedWork W2319779375 @default.
• W4296841146 hasRelatedWork W2372154413 @default.

• next